Replies to post #205623 on Biotech Values

[DewDiligence]

4Q16 HCV/ GT1: Harvoni vs Viekira* vs Zepatier ($ M)

[Table excludes GILD’s Epclusa and standalone Sovaldi,
which are almost exclusively used for GT2/GT3 patients.]

 
 Worldwide  
 Harvoni         1640  75.2% 
 Viekira          311  14.2% 
 Zepatier         229  10.5% 
 ========        ==== ====== 
 Total           2180 100.0% 
  
 US  
 Harvoni          976  79.0% 
 Viekira           54   4.4% 
 Zepatier        †206  16.7% 
 ========        ==== ====== 
 Total           1236 100.0% 
  
 Ex-US  
 Harvoni          664  70.3% 
 Viekira          257  27.2% 
 Zepatier         †23   2.4% 
 ========        ==== ====== 
                  944 100.0%

†Estimated.

*Includes Viekirax/Technivie (2-DAA) brands.